Search

Calmare NJ USA

Tag

Chemotherapy-induced Peripheral Neuropathy

Dr. Loprinzi from Mayo Clinic reports outstanding outcomes using Calmare scrambler therapy

Reuters video image

By Dr. Michael J. Cooney

I was very pleased to see this national media report from reporter Ben Gruber at Reuters News Service about a doctor at Mayo Clinic who is achieving very positive cancer patient outcomes using Calmare scrambler therapy to treat post-treatment pain.

Chemotherapy-induced peripheral neuropathy is a common but extremely painful condition many cancer patients suffer from as a side effect after chemotherapy treatment. Finding successful pain management solutions to treat this debilitating pain have been particularly challenging.

mayo clinicBut Dr. Charles L. Loprinzi, a highly regarded oncologist and professor at  the Mayo Clinic, has been conducting clinical trials using scrambler therapy to help cancer patients for the past three years. Today, he’s sharing his positive findings with the national media about his success using the scrambler machine.

The majority of chronic pain patients we have seen here at Calmare Therapy NJ are being treated for severe chronic pain for additional neuropathic conditions —  fibromyalgia, shingles, complex regional pain syndrome (CRPS) and post-surgical pain.

The recovering cancer patients with CIPN we have treated to date have also experienced outstanding outcomes, however.

Cancer-related neuropathy affects 33% of cancer survivors

Chemotherapy is one of the most common (but powerful and often debilitating) treatments to combat several types of cancer. Thankfully, many patients survive as a result of this drug but thousands are left with chronic pain as a long-term side effect.

A new report states that a third of all cancer survivors experience long-term post-treatment pain after undergoing chemo:

CIPN_INFO Graphic

Calmare Pain Therapy Treatment received its initial FDA clearance as a treatment specifically for chemotherapy-induced peripheral neuropathy, or CIPN.

Here’s an account of a Calmare patient who came to us here in New Jersey from Europe to treat her ongoing post-chemo neuropathy.

Mayo Clinic has been engaged in Calmare scrambler clinical trials for the past two years. The Massey Cancer Center at VCU has also been engaged in fruitful research.

You can find another clinical trial/research performed by doctors and researchers at the Paul Carbone Cancer Center at the University of Wisconsin here https://calmaretherapynj.com/clinical-trials-2/u-of-wisconsin-madison-cipn/

Teaching hospitals using Calmare Therapy

The device is currently being used in the U.S. at these key teaching hospitals:

  • Virginia Commonwealth University’s Massey Cancer Center
  • Paul Carbone Cancer Center at University of Wisconsin-Madison

We talk with patients and families every day about pain

If you or a loved one is dealing with pain after chemotherapy treatment, you know how difficult it can be. Dr. Michael Cooney talks with patients and families every day about if / how Calmare scrambler therapy treatment may help lessen or even alleviate CIPN. Feel free to reach out to the Calmare NJ team.

Is Calmare Therapy right for your chronic pain condition?

In order for patients to achieve the most positive outcomes from any therapy, treatment or medication, the solution must be appropriate for the specific condition being treated. Calmare Therapy is beneficial for patients living with treatment-resistant neuropathic chronic pain for a year or more as a result of these types of conditions:

  • Chronic pain syndrome
  • Cancer-related neuropathy
  • Chemotherapy-induced peripheral neuropathy (CIPN)
  • Reflex sympathetic dystrophy (RSD)
  • Fibromyalgia
  • Pain neuropathy
  • Radiating pain
  • Diabetic pain
  • Lower back pain
  • Chronic neck pain
  • Failed back surgery syndrome
  • Phantom limb syndrome
  • Sciatica

Calmare Pain Therapy Treatment® technology is FDA-cleared, non-invasive and pain-free. Unlike debilitating painkilling drugs, this therapy has no side effects. To learn more, tour our site and call (201) 933 – 4440 to learn more.

New U. of Wisconsin study supports Calmare for CIPN treatment

More and more cancer patients are surviving the disease but suffer with debilitating pain as a result of chemotherapy treatment, particularly in the feet and hands. The nerve damage can affect the patient’s ability to walk and use their hands. But an NBC News affiliate broadcast this new report on October 11 about a new  clinical study by the University of Wisconsin which determined Calmare’s MC-5A scrambler therapy is the first known therapy to show measurable results in helping to alleviate CIPN pain. “This technology has consistently shown very impressive results in our blind study, ” reports Toby Campbell, MD, chief of Palliative Medicine, University of Wisconsin.

As a result, a larger more extensive study has been approved. For anyone interested in participating in the study at the University of Wisconsin-Madison, call 800-622-8922.

Dr. Michael J. Cooney

Rutherford Allied Medical Group

Calmare Pain Therapy Treatment Proven to Combat Chemotherapy-induced Peripheral Neuropathy (CIPN)

One of the questions I’m asked most frequently about Calmare Pain Therapy Treatment is why did we choose it for our practice? My team and I spent years researching, interviewing and visiting manufacturers who produce technology to alleviate chronic pain. One of the decisive factors was a scientific report published last year by Thomas J. Smith, MD, Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit at Virginia Commonwealth University’s Massey Cancer Center.

The study, one of the first detailed studies conducted in the United States since FDA clearance, concluded, “Patient-specific cutaneous electrostimulation with the MC5-A Calmare device appears to dramatically reduce pain in refractory CIPN patients with no toxicity.” CIPN, a debilitating side effect for 30 – 40 percent of cancer patients, causes sharp ongoing pain in the hands and feet and affects an estimated four million cancer patients in the United States alone.

 Their specific findings:

 ·        Calmare Pain Therapy Treatment relieved refractory (resistant) CIPN pain quickly and significantly, with virtually no side effects.

  • Patients experienced a 64% reduction in pain, on average.
  • Four of 16 patients had a complete disappearance of pain.
  • Some patients had return of complete or partial normal sensation and relief of numbness, as well as relief of pain.
  • Some pain relief is durable for months but may require re-treatment and maintenance.

For those of us with expertise in pain management, these data findings are astounding. We learned that Calmare could be equally successful in the treatment of other types of chronic pain that are resistant to traditional therapy and medication, such as:

·         Neck and back pain

·         RSD

·         Pain as a result of other chronic diseases

As the first and only pain treatment facility in New Jersey, and one of fewer than 20 in the nation to offer Calmare, we know firsthand this therapy can be successful for many, many pain sufferers.

Just a few months ago, the Mayo Clinic announced it would launch its own Calmare study, and we look forward to sharing their findings with you as well.

Dr. Michael Cooney

Rutherford Allied Medical Group

 

Blog at WordPress.com.

Up ↑

<span>%d</span> bloggers like this: